Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery

被引:51
作者
Prasad, Mayuri S. [1 ]
Bhole, Ritesh P. [2 ]
Khedekar, Pramod B. [1 ]
Chikhale, Rupesh, V [3 ]
机构
[1] Rashtrasant Tukadoji Maharaj Nagpur Univ, Dept Pharmaceut Sci, Nagpur 440033, Maharashtra, India
[2] Dr DY Patil Inst Pharmaceut Sci & Res, Pune 411018, Maharashtra, India
[3] UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England
关键词
Tuberculosis; Enoyl acyl carrier protein reductase (InhA); Multi-drug resistant TB; INH-NAD adduct; Kat G; SUBSTRATE-BINDING LOOP; ACP REDUCTASE; CRYSTAL-STRUCTURE; MYCOLIC ACIDS; ISONIAZID RESISTANCE; POTENT INHIBITORS; TUBERCULOSIS INHA; RESIDENCE TIME; APO-FORM; IDENTIFICATION;
D O I
10.1016/j.bioorg.2021.105242
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Enoyl acyl carrier protein reductase (InhA) is a key enzyme involved in fatty acid synthesis mainly mycolic acid biosynthesis that is a part of NADH dependent acyl carrier protein reductase family. The aim of the present literature is to underline the different scaffolds or enzyme inhibitors that inhibit mycolic acid biosynthesis mainly cell wall synthesis by inhibiting enzyme InhA. Various scaffolds were identified based on the screening technologies like high throughput screening, encoded library technology, fragment-based screening. The compounds studied include indirect inhibitors (Isoniazid, Ethionamide, Prothionamide) and direct inhibitors (Triclosan/ Diphenyl ethers, Pyrrolidine Carboxamides, Pyrroles, Acetamides, Thiadiazoles, Triazoles) with better efficacy against drug resistance. Out of the several scaffolds studied, pyrrolidine carboxamides were found to be the best molecules targeting InhA having good bioavailability properties and better MIC. This review provides with a detailed information, analysis, structure activity relationship and useful insight on various scaffolds as InhA inhibitors.
引用
收藏
页数:25
相关论文
共 72 条
  • [1] Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis
    Alangaden, GJ
    Kreiswirth, BN
    Aouad, A
    Khetarpal, M
    Igno, FR
    Moghazeh, SL
    Manavathu, EK
    Lerner, SA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) : 1295 - 1297
  • [2] Impact of isoniazid resistance on virulence of global and south Indian clinical isolates of Mycobacterium tuberculosis
    Ameeruddin, Nusrath Unissa
    Elizabeth, Hanna Luke
    [J]. TUBERCULOSIS, 2014, 94 (06) : 557 - 563
  • [3] Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis
    Bhat, Zubair Shanib
    Rather, Muzafar Ahmad
    Maqbool, Mubashir
    UL Lah, Hafiz
    Yousuf, Syed Khalid
    Ahmad, Zahoor
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2017, 95 : 1520 - 1534
  • [4] Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis
    Bonnac, Laurent
    Gao, Guang-Yao
    Chen, Liqiang
    Felczak, Krzysztof
    Bennett, Eric M.
    Xu, Hua
    Kim, TaeSoo
    Liu, Nina
    Oh, HyeWon
    Tonge, Peter J.
    Pankiewicz, Krzysztof W.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (16) : 4588 - 4591
  • [5] ENCODED COMBINATORIAL CHEMISTRY
    BRENNER, S
    LERNER, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (12) : 5381 - 5383
  • [6] Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis
    Camacho, LR
    Ensergueix, D
    Perez, E
    Gicquel, B
    Guilhot, C
    [J]. MOLECULAR MICROBIOLOGY, 1999, 34 (02) : 257 - 267
  • [7] Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil
    Cardosa, Rosilene Fressatti
    Cardosa, Marco Antonio
    Fujimura Leite, Clarice Queico
    Sato, Daisy Nakamura
    Mamizuka, Elsa Masae
    Crespo Hirata, Rosario Dominguez
    de Mello, Fernando Fiuza
    Hirata, Mario Hiroyuki
    [J]. MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2007, 102 (01): : 59 - 61
  • [8] Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis
    Chikhale, Rupesh V.
    Barmade, Mahesh A.
    Murumkar, Prashant R.
    Yadav, Mange Ram
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (19) : 8563 - 8593
  • [9] An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors
    Chollet, Aurelien
    Maveyraud, Laurent
    Lherbet, Christian
    Bernardes-Genisson, Vania
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 146 : 318 - 343
  • [10] Crystal structure of the enoyl-ACP reductase of Mycobacterium tuberculosis (InhA) in the apo-form and in complex with the active metabolite of isoniazid pre-formed by a biomimetic approach
    Chollet, Aurelien
    Mourey, Lionel
    Lherbet, Christian
    Delbot, Alexandra
    Julien, Sylviane
    Baltas, Michel
    Bernadou, Jean
    Pratviel, Genevieve
    Maveyraud, Laurent
    Bernardes-Genisson, Vania
    [J]. JOURNAL OF STRUCTURAL BIOLOGY, 2015, 190 (03) : 328 - 337